23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel

SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members.

Nightingale’s Remote Health Check accurately measures dozens of biomarkers from a single blood sample, including cholesterols, apolipoproteins and fatty acids like omega-3. Many of these blood biomarkers have established clinical relationships to disease and can help guide important lifestyle interventions – such as diet and exercise. This pilot marks an important milestone in making blood testing more efficient and accessible.

23andMe currently offers its annual members the option for blood testing and provides interactive tools like HealthTracks, a feature that incorporates customer lifestyle choices into calculating a lifetime risk of disease. Blood biomarkers may improve the accuracy of these predictions and provide more direct insight into the kinds of interventions that may be most impactful to a customer’s health.

As part of the pilot, 23andMe will offer up to 5,000 23andMe+ Premium and Total Health members the opportunity to receive blood testing through Nightingale’s Remote Health Check at no cost to them. The pilot will evaluate customer feedback around blood testing, at-home sample collection, and the utility of the data when coupled with 23andMe’s established personal genetics products.

23andMe and Nightingale Health have a shared vision to help individuals identify health risks and prevent disease through proactive testing, treatment, coaching and behavior change. Together, the companies’ technologies allow for a more comprehensive assessment of a customer’s health and continuous tracking of progress toward their goals.

“We are truly impressed with Nightingale Health’s capabilities in blood biomarker testing. Their work with public biobank projects and resulting publications have previewed the exciting potential for metabolomics in prediction. We believe this collaboration will ultimately help our customers lead longer, healthier lives,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “We are enthusiastic about long-term opportunities that combine the power of our technologies.”

“This collaboration enables a globally unique feature set for 23andMe’s consumer health services. Together, we can help customers track and improve their health with regular blood testing using Nightingale Health’s technology,” said Teemu Suna, CEO and Founder of Nightingale Health. “This marks an important step in the execution of Nightingale Health’s strategy, as it announces an important partnership providing access to the consumer health market.”

About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit www.23andme.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “predicts,” “continue,” “will,” “schedule,” and “would” or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.

For further information, please contact:
23andMe
press@23andme.com
investors@23andme.com